Heron Therapeutics, Inc. (HRTX) stock
HRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
$0.28−0.00 (-0.74%)
Close on Nov 17, 2026Market cap $53.58MP/E –Yield –
Heron Therapeutics profit margin
Profit margin (net margin) is net income as a percentage of revenue.
Heron Therapeutics's profit margin for the twelve months ending Jun 30, 2026 was -22.5%. For fiscal 2025 it was -13.0%, against -9.4% the year before. The highest annual figure on record is -9.4% in fiscal 2024.
Annual profit margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -13.0% | −3.6 |
| FY2024 | Dec 31, 2024 | -9.4% | +77.6 |
| FY2023 | Dec 31, 2023 | -87.0% | +82.0 |
| FY2022 | Dec 31, 2022 | -169.1% | +86.5 |
| FY2021 | Dec 31, 2021 | -255.6% | +0.8 |
| FY2020 | Dec 31, 2020 | -256.4% | −116.1 |
| FY2019 | Dec 31, 2019 | -140.3% | +90.6 |
| FY2018 | Dec 31, 2018 | -230.8% | +411.0 |
| FY2017 | Dec 31, 2017 | -641.9% | +12895.5 |
| FY2016 | Dec 31, 2016 | -13537.4% | – |
Quarterly profit margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -14.6% | −8.2 |
| Q1 FY2026 | Mar 31, 2026 | -23.4% | −30.1 |
| Q4 FY2025 | Dec 31, 2025 | -7.3% | −16.3 |
| Q3 FY2025 | Sep 30, 2025 | -45.8% | −31.0 |
| Q2 FY2025 | Jun 30, 2025 | -6.4% | +19.2 |
| Q1 FY2025 | Mar 31, 2025 | 6.8% | +15.9 |
| Q4 FY2024 | Dec 31, 2024 | 9.0% | +40.3 |
| Q3 FY2024 | Sep 30, 2024 | -14.8% | +64.8 |
| Q2 FY2024 | Jun 30, 2024 | -25.6% | +106.8 |
| Q1 FY2024 | Mar 31, 2024 | -9.1% | +101.5 |
| Q4 FY2023 | Dec 31, 2023 | -31.3% | +34.8 |
| Q3 FY2023 | Sep 30, 2023 | -79.6% | +78.2 |
| Q2 FY2023 | Jun 30, 2023 | -132.4% | +71.6 |
| Q1 FY2023 | Mar 31, 2023 | -110.6% | +161.7 |
| Q4 FY2022 | Dec 31, 2022 | -66.2% | +198.4 |
| Q3 FY2022 | Sep 30, 2022 | -157.8% | +67.8 |
| Q2 FY2022 | Jun 30, 2022 | -204.0% | +67.9 |
| Q1 FY2022 | Mar 31, 2022 | -272.4% | −9.5 |
| Q4 FY2021 | Dec 31, 2021 | -264.6% | +37.7 |
| Q3 FY2021 | Sep 30, 2021 | -225.6% | +66.0 |
| Q2 FY2021 | Jun 30, 2021 | -271.9% | −28.4 |
| Q1 FY2021 | Mar 31, 2021 | -262.8% | −59.8 |
| Q4 FY2020 | Dec 31, 2020 | -302.3% | −137.2 |
| Q3 FY2020 | Sep 30, 2020 | -291.7% | −212.8 |
| Q2 FY2020 | Jun 30, 2020 | -243.5% | −106.5 |
| Q1 FY2020 | Mar 31, 2020 | -203.1% | −3.7 |
| Q4 FY2019 | Dec 31, 2019 | -165.1% | +6.7 |
| Q3 FY2019 | Sep 30, 2019 | -78.8% | +115.0 |
| Q2 FY2019 | Jun 30, 2019 | -137.0% | +86.8 |
| Q1 FY2019 | Mar 31, 2019 | -199.4% | +252.5 |
| Q4 FY2018 | Dec 31, 2018 | -171.8% | +449.8 |
| Q3 FY2018 | Sep 30, 2018 | -193.8% | +294.6 |
| Q2 FY2018 | Jun 30, 2018 | -223.8% | +279.1 |
| Q1 FY2018 | Mar 31, 2018 | -451.8% | +933.9 |
| Q4 FY2017 | Dec 31, 2017 | -621.6% | +3128.4 |
| Q3 FY2017 | Sep 30, 2017 | -488.4% | – |
| Q2 FY2017 | Jun 30, 2017 | -502.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -1385.7% | – |
| Q4 FY2016 | Dec 31, 2016 | -3750.0% | – |
See a number that looks wrong?